FloraSeq enters into agreement with the Medical College of Wisconsin to conduct clinical research study of FloraSeq’s FS-0809 capsules for treating recurrent Clostridium difficile (C. diff).
FloraSeq is proud to be one of nine winners of a Wisconsin Innovation Award (www.wisconsininnovationawards.com). Out of 180+ nominees, the 35 finalists were whittled down over a couple rounds of submissions and judging, with awards being announced Aug 16th in UW-Madison’ Union Theater. We were honored to be part of this great event celebrating an impressive array of innovations coming out of WI. Story in Milwaukee Journal Sentinel featured a picture of our capsules.
FloraSeq’s Karen Harrington and Steve Visuri are featured speakers at the BioForward (www.bioforward.org) Speaker Series: Introducing the Microbiome.
FloraSeq selected as a finalist for the Wisconsin Innovation Awards! (http://www.wisconsininnovationawards.com)
Great article in Milwaukee Journal Sentinel about FloraSeq. Read it here: FloraSeq LLC’s ‘poop pill’ not for the squeamish
We are excited to announce that we have received a seed-stage round of funding from BrightStar of Wisconsin (www.brightstarwi.org)! This proof-of-principal funding will largely go towards pre-clinical studies of performance in patients suffering from recurrent C. diff and who would otherwise be candidates for traditional Fecal Microbiota Transplant. The data will be important in establishing that the freeze-dried capsules are effective in small scale studies and will support “fast-track” FDA regulatory filings
FloraSeq was chosen among nine finalists to present our business opportunity to an international panel of biotech professionals and venture investor judges at the first Healthcare Innovation Pitch event coordinated by the non-profit accelerator Bridge-to-Cures. The mission of the event was to strengthen regional partnerships and create a stronger startup hub within the healthcare sector.
FloraSeq has been selected to present at the Wisconsin Angel Network Investors Track during the 2015 Early Stage Symposium in Madison, WI. The 2-day conference is designed to unlock Wisconsin’s entrepreneurial potential by bringing together entrepreneurs and investors, highlighting promising start-ups, and providing instruction and advice.
FloraSeq’s founders, Karen Harrington and Steve Visuri, have been selected to participate in the NSF-funded Innovation-Corps (I-Corps) program. Combining experience and guidance from established entrepreneurs with a targeted curriculum, the I-Corps program teaches participants to identify valuable product opportunities and offers entrepreneurship training critical to the success of early stage companies.
FloraSeq’s application has been accepted into the final round of competition in Marquette University’s ImpactNext Business Plan Contest. The competition is scheduled for Apr 21 and consists of a poster presentation and pitch to judges followed by “Shark Tank” style presentation and Q&A for finalists. (http://business.marquette.edu/centers-and-programs/impactnext)
FloraSeq advances to the finalist round of the Wisconsin Governor’s Business Plan Contest. The 24 contestants advancing have survived two rounds of judging in the contest organized through the Wisconsin Technology Council. The contest began with 238 entries. Finalists will submit 15- to 20-page business plans for review and the “diligent dozen” will present their business opportunities during the Wisconsin Entrepreneurs’ Conference, June 2 at the Alliant Energy Center in Madison.(http://govsbizplancontest.com/2015/from-software-to-medical-devices-to-hunting-biz-plan-contest-finalists-show-states-tech-range/)
The Wisconsin Economic Development Corporation (WEDC) has approved FloraSeq, LLC for investor tax credits under the Qualified New Business Venture Program.
FloraSeq wins the Elevator Pitch Olympics “People’s Choice Award” at the 2014 Early Stage Symposium in Madison, WI! Steven Visuri from FloraSeq presented a company overview to a panel of investor judges and an audience of a few hundred conference attendees. FloraSeq was chosen by the audience as the winner from among 18 companies selected to present.